Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 13, 2021 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma

NEW YORK and SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
September 09, 2021 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2021

NEW YORK and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
September 02, 2021 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

NEW YORK and SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
September 01, 2021 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3

NEW YORK and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
August 12, 2021 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles Dosed the first patient in a potentially registrational Phase 2 trial of ZN-c3 in...
August 04, 2021 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference

NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
August 02, 2021 07:30 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma

NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
August 02, 2021 07:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentera Therapeutics Announces Closing of $75 Million Series B Financing

SHANGHAI, China, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentera Therapeutics, a clinical-stage biopharmaceutical company with headquarters in Shanghai, China, today announced the successful completion of...
July 01, 2021 16:01 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
June 28, 2021 21:09 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock

NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...